COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes
- PMID: 34722593
- PMCID: PMC8549676
- DOI: 10.3389/fmed.2021.757510
COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes
Abstract
This systematic review aimed to provide an overview of the clinical profile and outcome of COVID-19 infection in patients with hemoglobinopathy. The rate of COVID-19 mortality and its predictors were also identified. A systematic search was conducted in accordance with PRISMA guidelines in five electronic databases (PubMed, Scopus, Web of Science, Embase, WHO COVID-19 database) for articles published between 1st December 2019 to 31st October 2020. All articles with laboratory-confirmed COVID-19 cases with underlying hemoglobinopathy were included. Methodological quality was assessed using the Joanna Briggs Institute (JBI) critical appraisal checklists. Thirty-one articles with data on 246 patients with hemoglobinopathy were included in this review. In general, clinical manifestations of COVID-19 infection among patients with hemoglobinopathy were similar to the general population. Vaso-occlusive crisis occurred in 55.6% of sickle cell disease patients with COVID-19 infection. Mortality from COVID-19 infection among patients with hemoglobinopathy was 6.9%. After adjusting for age, gender, types of hemoglobinopathy and oxygen supplementation, respiratory (adj OR = 89.63, 95% CI 2.514-3195.537, p = 0.014) and cardiovascular (adj OR = 35.20, 95% CI 1.291-959.526, p = 0.035) comorbidities were significant predictors of mortality. Patients with hemoglobinopathy had a higher mortality rate from COVID-19 infection compared to the general population. Those with coexisting cardiovascular or respiratory comorbidities require closer monitoring during the course of illness. More data are needed to allow a better understanding on the clinical impact of COVID-19 infections among patients with hemoglobinopathy. Clinical Trial Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020218200.
Keywords: COVID-19; hemoglobinopathies; severe acute respiratory syndrome coronavirus 2; sickle cell disease; systematic review; thalassemia.
Copyright © 2021 Lee, Chieng, Lau and Tan.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Role of Serum Ferritin in Predicting Outcomes of COVID-19 Infection Among Sickle Cell Disease Patients: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2022 May 30;9:919159. doi: 10.3389/fmed.2022.919159. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35712092 Free PMC article.
-
Hemoglobinopathy and pediatrics in the time of COVID-19.Hematol Transfus Cell Ther. 2021 Jan-Mar;43(1):87-100. doi: 10.1016/j.htct.2020.11.002. Epub 2020 Dec 2. Hematol Transfus Cell Ther. 2021. PMID: 33289008 Free PMC article. Review.
-
T-Cell Subsets and Interleukin-10 Levels Are Predictors of Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2022 Apr 28;9:852749. doi: 10.3389/fmed.2022.852749. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35572964 Free PMC article.
-
Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: A systematic review of systematic reviews.Front Med (Lausanne). 2022 Nov 4;9:973030. doi: 10.3389/fmed.2022.973030. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36405588 Free PMC article.
-
Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis.Front Oncol. 2025 Jan 15;14:1506366. doi: 10.3389/fonc.2024.1506366. eCollection 2024. Front Oncol. 2025. PMID: 39882453 Free PMC article.
Cited by
-
Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves.Curr Res Microb Sci. 2023 Dec 12;6:100215. doi: 10.1016/j.crmicr.2023.100215. eCollection 2024. Curr Res Microb Sci. 2023. PMID: 38187999 Free PMC article.
-
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9. Cell Commun Signal. 2024. PMID: 38360719 Free PMC article. Review.
-
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders.Best Pract Res Clin Haematol. 2022 Sep;35(3):101375. doi: 10.1016/j.beha.2022.101375. Epub 2022 Aug 24. Best Pract Res Clin Haematol. 2022. PMID: 36494144 Free PMC article. Review.
-
Demographic Characteristics, Comorbidities, and Length of Stay of COVID-19 Patients Admitted Into Intensive Care Units in Saudi Arabia: A Nationwide Retrospective Study.Front Med (Lausanne). 2022 Jul 13;9:893954. doi: 10.3389/fmed.2022.893954. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35911421 Free PMC article.
-
Differences in the distribution of hemoglobin variants according to the geographic regions in a Colombian population.Hematol Transfus Cell Ther. 2023 Jul;45 Suppl 2(Suppl 2):S140-S147. doi: 10.1016/j.htct.2022.11.012. Epub 2023 Jan 31. Hematol Transfus Cell Ther. 2023. PMID: 36764860 Free PMC article.
References
-
- Yang BY, Barnard LM, Emert JM, Drucker C, Schwarcz L, Counts CR, et al. . Clinical characteristics of patients With Coronavirus Disease 2019 (COVID-19) receiving emergency medical services in King County, Washington. JAMA Netw Open. (2020) 3:e2014549. 10.1001/jamanetworkopen.2020.14549 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources